NEWS
Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024
Agenus Inc. (Nasdaq: AGEN) announced that updated data from the clinical trial of botensilimab and balstilimab in refractory sarcomas will be presented at the ESMO Congress 2024 in Barcelona. The presentation will showcase updated efficacy and safety data from the ongoing Phase 1 trial, highlighting the potential of this combination therapy in treating patients with refractory sarcomas, including visceral angiosarcoma and leiomyosarcoma.
Botensilimab, a novel Fc-enhanced CTLA-4 inhibitor, and balstilimab, a PD-1 antibody, have shown promising clinical responses in multiple tumor types, including 'cold' tumors typically unresponsive to standard therapies. The presentation, titled 'Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase 1 study,' will be given by Dr. Breelyn A. Wilky on September 13th, 2024.
Botensilimab, a novel Fc-enhanced CTLA-4 inhibitor, and balstilimab, a PD-1 antibody, have shown promising clinical responses in multiple tumor types, including 'cold' tumors typically unresponsive to standard therapies. The presentation, titled 'Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase 1 study,' will be given by Dr. Breelyn A. Wilky on September 13th, 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2627Followers
107Following
28KVisitors
Follow